Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NewAmsterdam Pharma N.V.

    NASDAQ: NAMS · Real-Time Price · USD
    19.75
    -0.46 (-2.28%)
    At close: Jun 16, 2025, 3:59 PM
    19.32
    -2.18%
    Pre-market: Jun 17, 2025, 04:18 AM EDT

    NewAmsterdam Pharma Statistics

    Share Statistics

    NewAmsterdam Pharma has 112.27M shares outstanding. The number of shares has increased by 22.04% in one year.

    Shares Outstanding

    n/a
    		 112.27M

    Shares Change (YoY)

    n/a
    		 22.04%

    Shares Change (QoQ)

    n/a
    		 2.79%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 62.21M

    Failed to Deliver (FTD) Shares

    n/a
    		 11,675

    FTD / Avg. Volume

    n/a
    		 1.3%

    Short Selling Information

    The latest short interest is 6.56M, so 5.84% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.56M

    Short % of Shares Out

    n/a
    		 5.84%

    Short % of Float

    n/a
    		 6.97%

    Short Ratio (days to cover)

    n/a
    		 12.49

    Valuation Ratios

    The PE ratio is -10.04 and the forward PE ratio is -10.16. NewAmsterdam Pharma's PEG ratio is -0.53.

    PE Ratio

    n/a
    		 -10.04

    Forward PE

    n/a
    		 -10.16

    PS Ratio

    n/a
    		 53.22

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 3.2

    P/FCF Ratio

    n/a
    		 -15.23

    PEG Ratio

    n/a
    		 -0.53
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for NewAmsterdam Pharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.08, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 8.08

    Quick Ratio

    n/a
    		 8.08

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $670,044.12

    Profits Per Employee

    n/a
    		 $-3,552,911.76

    Employee Count

    n/a
    		 68

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1K

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 10.71% in the last 52 weeks. The beta is -0.03, so NewAmsterdam Pharma's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.03

    52-Week Price Change

    n/a
    		 10.71%

    50-Day Moving Average

    n/a
    		 18.23

    200-Day Moving Average

    n/a
    		 20.14

    Relative Strength Index (RSI)

    n/a
    		 52.68

    Average Volume (20 Days)

    n/a
    		 898,246

    Income Statement

    In the last 12 months, NewAmsterdam Pharma had revenue of 45.56M and earned -241.6M in profits. Earnings per share was -2.56.

    Revenue

    n/a
    		 45.56M

    Gross Profit

    n/a
    		 45.56M

    Operating Income

    n/a
    		 -176.29M

    Net Income

    n/a
    		 -241.6M

    EBITDA

    n/a
    		 -241.49M

    EBIT

    n/a
    		 -241.6M

    Earnings Per Share (EPS)

    n/a
    		 -2.56
    Full Income Statement

    Balance Sheet

    The company has 771.74M in cash and 448K in debt, giving a net cash position of 771.29M.

    Cash & Cash Equivalents

    n/a
    		 771.74M

    Total Debt

    n/a
    		 448K

    Net Cash

    n/a
    		 771.29M

    Retained Earnings

    n/a
    		 n/a

    Total Assets

    n/a
    		 818.41M

    Working Capital

    n/a
    		 776.39M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -158.56M and capital expenditures -672K, giving a free cash flow of -159.24M.

    Operating Cash Flow

    n/a
    		 -158.56M

    Capital Expenditures

    n/a
    		 -672K

    Free Cash Flow

    n/a
    		 -159.24M

    FCF Per Share

    n/a
    		 -1.69
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -386.91% and -530.25%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -386.91%

    Pretax Margin

    n/a
    		 -530.25%

    Profit Margin

    n/a
    		 -530.25%

    EBITDA Margin

    n/a
    		 -530%

    EBIT Margin

    n/a
    		 -386.91%

    FCF Margin

    n/a
    		 -349.49%

    Dividends & Yields

    NAMS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NAMS is $42, which is 112.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $42

    Price Target Difference

    n/a
    		 112.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 28.86

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist